Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial

Nadia Harbeck, Chiun Sheng Huang, Sara Hurvitz, The LUX-Breast 1 study group, Gunta Purkalne (Member of the Working Group), Iveta Kudaba (Member of the Working Group)

Research output: Contribution to journal › Article › peer-review

111 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science